Xi Jun-Yu, Wei Zhong-Yi, Zhang Qiang, Xie Yan-Ming
Institute of Basic Medicine in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
Zhongguo Zhong Yao Za Zhi. 2024 Jan;49(1):279-284. doi: 10.19540/j.cnki.cjcmm.20230918.501.
This study systematically combed the existing evidence of Houyanqing Oral Liquid in the treatment of acute pharyngitis from the "6+1" dimensions of safety, effectiveness, economy, innovation, suitability, accessibility, and characteristics of traditional Chinese medicine(TCM) and carried out qualitative and quantitative analysis of the data from each dimension. The multi-criteria decision analysis(MCDA) model and CSC v2.0 were used to evaluate the clinical value of this drug, so as to provide evidence for the selection of essential drugs in the department of otolaryngology and for medical and health decision-making. The dimensions are graded A, B, C, or D. The adverse reactions of Houyanqing Oral Liquid in the treatment of acute pharyngitis were mainly manifested as abdominal pain, diarrhea, rash, etc., which were relieved after drug withdrawal. In terms of safety, it was considered that Houyanqing Oral Liquid had controllable risk and high safety, which was rated as grade B. Compared with ribavirin aerosol alone, Houyanqing Oral Liquid combined with ribavirin aerosol can significantly improve the total response rate, shorten the time to abatement of fever and di-sappearance of throat pain and mucosal congestion, and alleviate mucosal congestion and cough with sputum. With medium-quality evidence, the effectiveness was rated as grade B. Compared with ribavirin aerosol alone, Houyanqing Oral Liquid combined with ribavirin aerosol had cost-effectiveness advantages in the treatment of acute pharyngitis, and its economy was rated as grade C with the evidence of general quality. For acute pharyngitis, Houyanqing Oral Liquid can shorten the disease course and obviously relieve sore throat. Moreover, it can be used for the treatment of radioactive pharyngitis and oral ulcer, and thus its innovation was rated as grade B. With convenient and simple administration and standard and complete drug information, the suitability of this drug was rated as grade B. Houyanqing Oral Liquid is derived from the folk prescription in Hunan province and has been subjected to real-world studies, and thus the TCM characteristics was rated as grade B. According to the ratings of all the dimensions, the comprehensive value of Houyanqing Oral Liquid in the clinical treatment of acute pharyngitis was determined as grade B, with sufficient evidence and clear results. It is suggested that the results should be conditionally converted into relevant policy of clinical basic drug management according to procedures.
本研究从安全性、有效性、经济性、创新性、适用性、可及性以及中医药特色“6+1”维度，系统梳理喉咽清口服液治疗急性咽炎的现有证据，并对各维度数据进行定性和定量分析。采用多标准决策分析（MCDA）模型及CSC v2.0对该药物的临床价值进行评价，为耳鼻咽喉科基本药物遴选及医疗卫生决策提供依据。各维度分为A、B、C、D四级。喉咽清口服液治疗急性咽炎的不良反应主要表现为腹痛、腹泻、皮疹等，停药后缓解。在安全性方面，认为喉咽清口服液风险可控、安全性高，评定为B级。与单用利巴韦林气雾剂相比，喉咽清口服液联合利巴韦林气雾剂可显著提高总有效率，缩短退热时间及咽痛、黏膜充血消失时间，减轻黏膜充血及咳嗽咳痰症状。依据中等质量证据，有效性评定为B级。与单用利巴韦林气雾剂相比，喉咽清口服液联合利巴韦林气雾剂在治疗急性咽炎方面具有成本效果优势，依据一般质量证据，经济性评定为C级。对于急性咽炎，喉咽清口服液可缩短病程，明显缓解咽痛，还可用于治疗放射性咽炎及口腔溃疡，因此创新性评定为B级。该药物服用方便、简单，药品信息规范、完整，适用性评定为B级。喉咽清口服液源于湖南省民间验方，且经过真实世界研究，中医药特色评定为B级。根据各维度评分，确定喉咽清口服液在急性咽炎临床治疗中的综合价值为B级，证据充分、结果明确。建议按程序将结果有条件转化为临床基本药物管理的相关政策。
